News

February 14, 2020February 14, 2020

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

News

A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian cancer ... Read more

February 12, 2020February 26, 2020

New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer

News

Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. DPX-Survivac, ... Read more

February 10, 2020February 10, 2020

France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments

News

Rubraca (rucaparib) is now available in France and eligible for reimbursement when used as a maintenance therapy by women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status, its developer, ... Read more

February 7, 2020February 7, 2020

New Progress Made in Developing Bio-ink for 3-D Printing Functional Human Ovaries, Researchers Report

News

Researchers at Northwestern University have identified and mapped the location of structural proteins within pig’s ovaries, which closely resemble human ovaries. This will help the development of an ovary-specific bio-ink ... Read more

January 31, 2020January 31, 2020

Nami Developing Targeted Nanoparticle Therapy for Advanced Forms of Ovarian Cancer

News

Nami Therapeutics is developing a new form of targeted therapy that aims to be more effective and less toxic than other treatments for advanced forms of ovarian cancer. The new ... Read more

January 30, 2020February 5, 2020

Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open

News

A Phase 1b/2 clinical trial testing Onxeo’s AsiDNA as a potential treatment to overcome resistance to Zejula (niraparib) in ovarian cancer patients is set to begin, part of an agreement ... Read more

January 28, 2020February 3, 2020

First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces

News

Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The ... Read more

January 27, 2020January 27, 2020

Cycle for Survival Kicks Off Fundraising Events With Goal to Surpass Last Year’s $42M

News

Cycle for Survival is kicking off the first of its high-energy indoor cycling events with the goal of surpassing the $42 million raised last year to help defeat rare malignancies ... Read more

January 24, 2020January 24, 2020

Mereo Licenses Navicixizumab to Oncologie for Worldwide Development, Commercialization

News

Mereo BioPharma has licensed its experimental therapy navicixizumab (OMP-305B83) — designed to treat advanced, heavily pretreated ovarian cancer — to Oncologie for worldwide development and commercialization. Under the terms of the ... Read more

January 23, 2020February 6, 2020

FDA Asked to Approve Test of Ovarian Cancers Likely to Respond to Zejula Maintenance Therapy

News

Myriad Genetics has filed a supplementary premarket approval (sPMA) application with the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify advanced ovarian cancer patients more likely ... Read more